Table 2.
Patient | Donor Source | HLA Match (of 6) | Total Nuc. Cell Dose (x107/kg) | GvH Prophylaxis | Granulocyte Infusions | Conditioning Regimen |
---|---|---|---|---|---|---|
1 | Sibling Bone Marrow | 6 | 79.4 | Csa/Mtx | No | Busulfan/Cytoxan |
2 | Sibling Bone Marrow | 6 | 16.6 | Csa/Mtx | No | Busulfan/Cytoxan |
3a* | Sibling Bone Marrow | 6 | NA | Csa/TCD | No | Fludarabine/Cytoxan + eATG |
3b | Sibling Bone Marrow | 6 | 40 | Csa/Mtx | No | Fludarabine/Busulfan/Cytoxan + rATG |
4 | Sibling Bone Marrow | 6 | 34.8 | Csa/Mtx | No | Busulfan/Cytoxan |
5a* | Unrelated Cord Blood | 5 | 4.15 | Csa/Steroid | Yes | Busulfan/Cytoxan + eATG |
5b | Unrelated Cord Blood | 5 | 4.14 | Csa/Steroid | Yes | TBI(200cGy)/Fludarabine/Cytoxan |
6 | Sibling Bone Marrow | 6 | 55 | Csa/Mtx | No | Busulfan/Cytoxan + eATG |
7a* | Unrelated Cord Blood | 5 | 8.5 | Csa/MMF | Yes | Fludarabine/Busulfan/Cytoxan + eATG |
7b | Unrelated Cord Blood | 4 | 6.87 | Csa/MMF | Yes | Campath/Fludarabine/Cytoxan |
8 | Unrelated Cord Blood | 5 | 3.47 | Csa/MMF | Yes | Fludarabine/Busulfan/Cytoxan + eATG |
9 | Unrelated Cord Blood | 5 | 4.8 | Csa/MMF | Yes | Fludarabine/Busulfan/Cytoxan + eATG |
10 | Sibling Cord Blood | 6 | 3.2 | Csa/Steroid | Yes | Fludarabine/Busulfan/Cytoxan + eATG |
11 | Unrelated Cord Blood | 5 | 12.6 | Csa/MMF | Yes | Fludarabine/Busulfan/Cytoxan + eATG |
12 | Unrelated Cord Blood | 6 | 11.2 | Csa/MMF | Yes | Fludarabine/Busulfan/Cytoxan + eATG |
ATG: Anti-thymocyte globulin, eATG: equine ATG, rATG: rabbit ATG. Csa: Cyclosporine, Mtx: Methotrexate, MMF: Mycophenolate Mofetil, TCD: T-cell depleted